Jianjian Chen

Jianjian Chen

Auto-generated profile, based on publicly available information

Jianjian Chen

Department of Radiology, Center of Interventional Radiology and Vascular Surgery, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2025 in Hepatology
Verified
Journal Article
Open access
ZJZhi-Cheng Jin
Zhi-Cheng Jin
JWJingwei Wei
Jingwei Wei
YXYu-Dong Xiao
Yu-Dong Xiao
ASAnfeng Si
Anfeng Si
JCJian-Jian Chen
Jian-Jian Chen
GTGao-Jun Teng
Gao-Jun Teng
Background and Aims: This study aims to quantify intratumoral heterogeneity (ITH) and identify prognostic imaging biomarkers in patients with HCC treated with transarterial chemoembolization combined with immune checkpoint inhibitor plus molecular targeted therapy (TACE-ICI-MTT). Approach and Results: This multicenter cohort study included 742 patients with unresectable HCC who received first-line TACE-ICI-MTT from January 2018 to December 2022. Radiomic features representing global tumor regions (GTRs) and ITH were extracted from pretreatment CT scans. A composite GTR-ITH score was generated using principal component analysis to integrate both GTR- and ITH-related features. Ensemble learning with multiple machine learning algorithms was employed to predict treatment response. Model performance was evaluated by the area under the receiver operating characteristic curve (AUC). Following feature selection, 17 GTR- and 27 ITH-related radiomic features were retained to construct the GTR-ITH score. The model demonstrated high discriminative performance, with AUCs of 0.94 in the training set, 0.82 in the internal validation set, and 0.83 in the independent test set. The GTR-ITH score was strongly associated with treatment response (OR: 34.39; p<0.001) and independently predicted overall survival (HR: 0.63; p=0.004). Patients classified as GTR-ITH low-risk consistently showed significantly prolonged progression-free survival and overall survival. To reveal the biological relevance of the radiomic score, immune infiltration patterns were characterized using bulk RNA sequencing data from the Cancer Imaging Archive. The GTR-ITH low-risk group also exhibited an immune-inflamed microenvironment characterized by enriched plasma cells and M1 macrophages, and reduced M2 macrophage infiltration. Conclusions: An imaging radiomic biomarker that captures both global and intratumoral heterogeneity robustly predicts response and survival in patients with HCC treated with TACE-ICI-MTT, and reflects underlying immune microenvironment phenotypes.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YYYuan Yao
Yuan Yao
DJDechao Jiao
Dechao Jiao
ZLZaoqu Liu
Zaoqu Liu
JCJianjian Chen
Jianjian Chen
XZXueliang Zhou
Xueliang Zhou
XHXinwei Han
Xinwei Han
Accumulating evidence has demonstrated that microRNAs (miRNAs or miRs) play an important role in the diagnosis and prognosis of tumors. In the case of cholangiocarcinoma (CCA), miRNAs may serve as potential tumor biomarkers and therapeutic targets. Based on The Cancer Genome Atlas (TCGA) database, fold change >2 was used to screen out miRNAs with differential expression in patients with CCA. Univariate and multivariate Cox regression analyses identified miR‐3913‐5p as an independent prognostic factor in patients with CCA. Overall survival and progression‐free survival of patients with CCA were analyzed based on clinical data from TCGA database. In addition, four datasets were combined to identify 21 possible target genes of miR‐3913, and Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were conducted to predict potential pathways and functions of the molecular target genes. Subsequently, the miRNAs associated with survival were selected to build the miRNA‐mRNA expression network. Furthermore, the differential expression of miR‐3913‐5p in CCA cells and normal bile duct epithelial cells was confirmed through in vitro experiments. The possible target genes (RNF24 and SIGLEC) were further screened by reverse transcription‐quantitative PCR. In addition, functional experiments showed that miR‐3913‐5p might be an oncogene that affects the proliferation and migration of CCA cells by inhibiting and mimicking miR‐3913‐5p. Therefore, miR‐3913 may serve as a biomarker for the diagnosis and prognosis of patients with CCA.

14 August 2021 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
XZXueliang Zhou
Xueliang Zhou
MDMengmeng Dou
Mengmeng Dou
ZLZaoqu Liu
Zaoqu Liu
DJDechao Jiao
Dechao Jiao
ZLZhaonan Li
Zhaonan Li
XHXinwei Han
Xinwei Han
Background. Hepatocellular carcinoma (HCC) remains an important cause of cancer death. The molecular mechanism of hepatocarcinogenesis and prognostic factors of HCC have not been completely uncovered. Methods. In this study, we screened out differentially expressed lncRNAs (DE lncRNAs), miRNAs (DE miRNAs), and mRNAs (DE mRNAs) by comparing the gene expression of HCC and normal tissue in The Cancer Genome Atlas (TCGA) database. DE mRNAs were used to perform Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Then, the miRNA and lncRNA/mRNA modules that were most closely related to the survival time of patients with HCC were screened to construct a competitive endogenous RNA (ceRNA) network by weighted gene coexpression network analysis (WGCNA). Moreover, univariable Cox regression and Kaplan-Meier curve analyses of DE lncRNAs and DE mRNAs were conducted. Finally, the lasso-penalized Cox regression analysis and nomogram model were used to establish a new risk scoring system and predict the prognosis of patients with liver cancer. The expression of survival-related DE lncRNAs was verified by qRT-PCR. Results. A total of 1896 DEmRNAs, 330 DElncRNAs, and 76 DEmiRNAs were identified in HCC and normal tissue samples. Then, the turquoise miRNA and turquoise lncRNA/mRNA modules that were most closely related to the survival time of patients with HCC were screened to construct a ceRNA network by WGCNA. In this ceRNA network, there were 566 lncRNA-miRNA-mRNA regulatory pairs, including 30 upregulated lncRNAs, 16 downregulated miRNAs, and 75 upregulated mRNAs. Moreover, we screened out 19 lncRNAs and 14 hub mRNAs related to prognosis from this ceRNA network by univariable Cox regression and Kaplan-Meier curve analyses. Finally, a new risk scoring system was established by selecting the optimal risk lncRNAs from the 19 prognosis-related lncRNAs through lasso-penalized Cox regression analysis. In addition, we established a nomogram model consisting of independent prognostic factors to predict the survival rate of HCC patients. Finally, the correlation between the risk score and immune cell infiltration and gene set enrichment analysis were determined. Conclusions. In conclusion, the results may provide potential biomarkers or therapeutic targets for HCC and the establishment of the new risk scoring system and nomogram model provides the new perspective for predicting the prognosis of HCC.

13 March 2017 in Journal of Nonlinear Sciences and Applications
Verified
Journal Article
Open access
JCJianjian Chen
Jianjian Chen
XHXianjiu Huang
Xianjiu Huang

25 July 2023 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
PDF file
JCJian-Jian Chen
Jian-Jian Chen
ZJZhi-Cheng Jin
Zhi-Cheng Jin
BLBiao Luo
Biao Luo
YWYu-Qing Wang
Yu-Qing Wang
RLRui Li
Rui Li
GTGao-Jun Teng
Gao-Jun Teng
Several first-line immune checkpoint inhibitor (ICI)-based combination therapies have been identified for unresectable hepatocellular carcinoma (uHCC). This network meta-analysis (NMA) aimed to provide the most updated evidence about the preferred first-line ICI-based regimens for uHCC.

23 March 2022 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
JLJuanfang Liu
Juanfang Liu
SXShanshan Xie
Shanshan Xie
XZXueliang Zhou
Xueliang Zhou
ZLZhaonan Li
Zhaonan Li
JCJianjian Chen
Jianjian Chen
XHXinwei Han
Xinwei Han